Completed PHASE1 INTERVENTIONAL 3-arm NCT01280175

Foster With or Without Charcoal Block or Aerochamber Plus

Pharmacokinetics and Lung Bioavailability of BDP/Formoterol HFA Fixed Combination After Single Administration in 12 Healthy Volunteers Using the Standard Actuator With or Without Charcoal Block or the Aerochamber Spacer.

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Healthy Volunteers

Interventions Aerochamber Plus spacer charcoal block pMDI standard actuator

Updated 6 times since 2017 Last updated: Jul 30, 2020 Started: Dec 31, 2006 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Volunteers and is currently completed. Chiesi Farmaceutici S.p.A. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.
Cross Research S.A.

Data source: Chiesi Farmaceutici S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Arzo, Switzerland